Abiopharma

Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong

Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer

New Form POS AM - RedHill Biopharma Ltd. Filed: 2025-09-05 AccNo: 0001178913-25-003257 Size: 1 MB

New Form POS AM - RedHill Biopharma Ltd. Filed: 2025-09-05 AccNo: 0001178913-25-003255 Size: 1 MB

Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

New Form 144 - Premier, Inc. Filed: 2025-09-05 AccNo: 0001959173-25-005787 Size: 4 KB

New Form SCHEDULE 13G/A - Forte Biosciences, Inc. Filed: 2025-09-05 AccNo: 0001623632-25-001195 Size: 45 KB

New Form 6-K/A - RedHill Biopharma Ltd. Filed: 2025-09-05 AccNo: 0001558370-25-011890 Size: 2 MB

New Form 10-K - iBio, Inc. Filed: 2025-09-05 AccNo: 0001558370-25-011888 Size: 16 MB

Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

New Form 6-K - Haleon plc Filed: 2025-09-05 AccNo: 0001654954-25-010432 Size: 78 KB

MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year